Skip to main
BNGO

Bionano Genomics (BNGO) Stock Forecast & Price Target

Bionano Genomics (BNGO) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Bionano Genomics is well-positioned in the growing markets of genetic disorders, infertility, and cell and gene therapy quality control, with its Saphyr system providing a highly sensitive method for genome analysis. The company has a strong cash position of $29.5M and may potentially need to raise additional capital within the next 12 months to fund operations. Risks include lower-than-projected market uptake and the need for further capital raise, but the potential market opportunity and current cash runway make Bionano Genomics a promising investment.

Bears say

Bionano Genomics is seeing declining revenues and increasing net losses, with only a 2.6% YoY decline in revenue for 4Q25 and a 7.4% decline for full-year 2025. Additionally, despite positive developments like the Bionano Symposium and the establishment of new CPT codes, adoption and utilization of the company's OGM technology has been slow, with only modest increases in installations and flowcell sales. The company's financial outlook for 2026 is also not very optimistic, with projected revenue growth of only 16%, leading to an adjusted price target of $6 from $7 per share. Overall, the company's financial performance and slow market adoption of their technology suggest a negative outlook for their stock.

Bionano Genomics (BNGO) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bionano Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bionano Genomics (BNGO) Forecast

Analysts have given Bionano Genomics (BNGO) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Bionano Genomics (BNGO) has a Strong Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bionano Genomics (BNGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.